It wasn't that long ago that Madrigal Pharmaceuticals was in a similar situation. A pre-commercial biotech with a promising ...

Life begins with a single fertilized cell that gradually transforms into a multicellular organism. This process requires ...

The ginormous "Magnificent Seven" stocks have been the stars of the stock market in recent years. In 2025, international ...

Transformative Growth Counseling expands Spanish-language individual therapy, providing culturally responsive mental health care for Spanish-speaking clients. NAPERVILLE, IL, UNITED STATES, December ...

The possibility of a long-awaited change in the treatment of male baldness has been raised by Cosmo Pharmaceuticals’ ...

Kyverna Therapeutics, Inc. ( (KYTX)) has provided an update. On December 15, 2025, Kyverna Therapeutics announced positive topline data from its Phase 2 trial of mivocabtagene autoleucel (miv-cel) for ...

Janux Therapeutics (JANX) on late Monday reported positive updated interim data for its JANX007, a PSMA-directed TRACTr, Phase 1 clinical program in patients with metastatic castration-resistant ...

Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve ...

The latest update is out from Apogee Therapeutics ( (APGE)). On November 10, 2025, Apogee Therapeutics announced positive interim Phase 1 results for APG333, which exceeded trial objectives and ...

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...